What does Semax + Selank Blend stack well with?

For female physiology protocols, Semax + Selank Blend pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from Semax + Selank Blend's primary mechanism (Same as Semax + Selank blend), producing additive or synergistic effects rather than receptor competition.

How does Semax + Selank Blend compare to Oxytocin and Kisspeptin?

Semax + Selank Blend (Nootropic + anxiolytic blend, Mixed half-life, 300-600 mcg each typical dose) differs from peers in the comparison table above. The principal points of difference relative to Oxytocin and Kisspeptin are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

What are the safety considerations for Semax + Selank Blend?

Excellent. For female hormonal and cyclical use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semax + Selank Blend's Mixed pharmacokinetic profile and intranasal/subq administration route influence the side-effect profile in predictable ways.

What is the standard dosing protocol for Semax + Selank Blend?

Conventional Semax + Selank Blend dosing is 300-600 mcg each 2-3x daily for 2-4 week courses via intranasal/subq. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of Semax + Selank Blend?

Semax + Selank Blend regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ Semax + Selank Blend

Semax + Selank Blend

Women's Health

For women considering Semax + Selank Blend, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. The compact name for the Semax + Selank blend formulation. The Mixed pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

Autoimmune SupportMenopauseLibido (Female)Endometriosis SupportPerimenopause

Key Takeaways

Female-physiology lens: Semax + Selank Blend response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Same as Semax + Selank blend.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 300-600 mcg each 2-3x daily for 2-4 week courses via intranasal/subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience Semax + Selank Blend. Same as Semax + Selank blend. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Semax + Selank Blend's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and Semax + Selank Blend's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Semax + Selank Blend is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Female Physiology Applications

Endometriosis Support

For endometriosis support in female users, Semax + Selank Blend is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

PCOS Support

PCOS Support is one of the dimensions on which women track Semax + Selank Blend response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Skin Health

In the perimenopausal window, Semax + Selank Blend for skin health produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Bone Density

For bone density in female users, Semax + Selank Blend is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300-600 mcg each	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180-600 mcg each	4–6 weeks initial cycle
Women's Health focus	Intranasal	300-600 mcg each	2-3x daily for 2-4 week courses
Maintenance phase	Intranasal	210-600 mcg each	Ongoing with periodic pauses

Dose timing for Semax + Selank Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semax + Selank Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Semax + Selank Blend + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Semax + Selank Blend's mechanism in female physiology protocols.
Semax + Selank Blend + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Semax + Selank Blend's mechanism in female physiology protocols.
Semax + Selank Blend + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Semax + Selank Blend's mechanism in female physiology protocols.
Semax + Selank Blend + Epithalon: Identified by Khavinson in St. Pairs naturally with Semax + Selank Blend's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved

Excellent.

Lens-specific safety considerations for female physiology use of Semax + Selank Blend: Excellent. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank GAD

PMID 21443549

Semax + Selank Blend vs Related Peptides

Compound	Profile	Onset	Best For
Semax + Selank Blend	Nootropic + anxiolytic blend	Mixed	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

How will Semax + Selank Blend interact with my cycle?

For pre-menopausal users, response to Semax + Selank Blend often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Can I use Semax + Selank Blend during pregnancy or while trying to conceive?

Most peptide therapeutics, including Semax + Selank Blend, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Will Semax + Selank Blend affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. Semax + Selank Blend's specific interaction follows its mechanism.

What is Semax + Selank Blend?

Semax + Selank Blend (also known as SS Blend) is a small nootropic + anxiolytic blend with a molecular weight of Variable and a plasma half-life of Mixed. Same as Semax + Selank blend. The compound is studied primarily in the female physiology domain for the applications outlined above.

How does Semax + Selank Blend's half-life affect dosing?

Semax + Selank Blend has a plasma half-life of Mixed, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 2-3x daily for 2-4 week courses dosing at 300-600 mcg each per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

Clinical Protocol

Start a Semax + Selank Blend Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Semax + Selank Blend and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Not on prohibited list
FDA: Unapproved

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax + Selank Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Semax + Selank Blend

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised